Featured Articles

1. The TIDES Manufacturing Mandate: Why Incrementalism Fails And Integration Prevail 5/7/2026

   Manufacturing strategies for peptides and oligonucleotides are being reshaped by scale, complexity, and chronic use. An integrated, end‑to‑end approach shows how early design decisions can prevent costly bottlenecks later.

2. Advancing TIDES Manufacturing Through Biocatalysis And Flow Technologies 4/17/2026

   Integrated biocatalysis and continuous processing are reshaping therapeutic manufacturing, enabling faster scale‑up, greater efficiency, and lower costs as peptides and oligonucleotides meet demands.

3. Drug Product Service 3/11/2026

   Gain clarity on how solid‑state science, targeted formulation platforms, and advanced manufacturing combine to boost stability, scalability, and readiness for clinical and commercial production.

4. A Decade Of Transforming Pharmaceutical Manufacturing 2/25/2026

   Modern enzyme engineering, automation, and AI are reshaping therapeutic development — accelerating design, improving efficiency, and enabling faster, more sustainable biopharma manufacturing.

    

5. Building the Next Generation of TIDES Manufacturing Excellence 2/12/2026

   Rising demand for complex TIDES therapies is shifting manufacturing expectations, driving adoption of continuous processing, digital tools, stronger supply strategies, and greener, scalable synthesis.

6. Inside The Shift Toward Greener, Faster, Smarter Drug Manufacturing 2/12/2026

   Manufacturers are using continuous processing, analytics, and enzyme‑driven chemistry to cut waste, accelerate development, and enable safer, adaptable workflows amid rising sustainability demands.

7. Unlocking The Potential Of Biocatalysis 1/22/2026

   Biocatalysis delivers cleaner, more selective pharma processes while cutting energy use and waste. Engineered enzymes broaden their reach, enabling faster development and greater sustainability.

8. Leveraging Flow Chemistry 1/22/2026

   Discover how continuous processing cuts waste, improves efficiency, and supports safer, scalable reactions while helping teams meet sustainability goals and speed development.

9. AsymBio Commences Commercial Operations At Fengxian Base 12/8/2025

   Shanghai, AsymBio, a technology-driven global Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem Group (stock code: 002821.SZ / 6821.HK), today announced the official start of commercial production at its Shanghai Fengxian Commercial Manufacturing Base.

10. Oligo-Ready 8/17/2022

    The benefits of continuous flow manufacturing are significant and numerous and those benefits grow with each technological breakthrough and methodological advance.